These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 19617341)

  • 1. Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans.
    Muzi M; Mankoff DA; Link JM; Shoner S; Collier AC; Sasongko L; Unadkat JD
    J Nucl Med; 2009 Aug; 50(8):1267-75. PubMed ID: 19617341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling cyclosporine A inhibition of the distribution of a P-glycoprotein PET ligand, 11C-verapamil, into the maternal brain and fetal liver of the pregnant nonhuman primate: impact of tissue blood flow and site of inhibition.
    Ke AB; Eyal S; Chung FS; Link JM; Mankoff DA; Muzi M; Unadkat JD
    J Nucl Med; 2013 Mar; 54(3):437-46. PubMed ID: 23359659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic Modeling of (
    García-Varela L; García DV; Kakiuchi T; Ohba H; Nishiyama S; Tago T; Elsinga PH; Tsukada H; Colabufo NA; Dierckx RAJO; van Waarde A; Toyohara J; Boellaard R; Luurtsema G
    Mol Pharm; 2021 Jan; 18(1):416-428. PubMed ID: 33315404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous PET imaging of P-glycoprotein inhibition in multiple tissues in the pregnant nonhuman primate.
    Eyal S; Chung FS; Muzi M; Link JM; Mankoff DA; Kaddoumi A; O'Sullivan F; Hebert MF; Unadkat JD
    J Nucl Med; 2009 May; 50(5):798-806. PubMed ID: 19403878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET.
    Wagner CC; Bauer M; Karch R; Feurstein T; Kopp S; Chiba P; Kletter K; Löscher W; Müller M; Zeitlinger M; Langer O
    J Nucl Med; 2009 Dec; 50(12):1954-61. PubMed ID: 19910428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET.
    Bankstahl JP; Kuntner C; Abrahim A; Karch R; Stanek J; Wanek T; Wadsak W; Kletter K; Müller M; Löscher W; Langer O
    J Nucl Med; 2008 Aug; 49(8):1328-35. PubMed ID: 18632828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation.
    Luurtsema G; Molthoff CF; Windhorst AD; Smit JW; Keizer H; Boellaard R; Lammertsma AA; Franssen EJ
    Nucl Med Biol; 2003 Oct; 30(7):747-51. PubMed ID: 14499333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analysis of 11C-verapamil transfer at the human blood-brain barrier for evaluation of P-glycoprotein function.
    Ikoma Y; Takano A; Ito H; Kusuhara H; Sugiyama Y; Arakawa R; Fukumura T; Nakao R; Suzuki K; Suhara T
    J Nucl Med; 2006 Sep; 47(9):1531-7. PubMed ID: 16954563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of P-glycoprotein function at the human blood-brain barrier using [
    Mossel P; Arif WM; De Souza GS; Varela LG; van der Weijden CWJ; Boersma HH; Willemsen ATM; Boellaard R; Elsinga PH; Borra RJH; Dierckx RAJO; Lammertsma AA; Bartels AL; Luurtsema G
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3917-3927. PubMed ID: 37552369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (R)-[11C]verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus.
    Syvänen S; Luurtsema G; Molthoff CF; Windhorst AD; Huisman MC; Lammertsma AA; Voskuyl RA; de Lange EC
    BMC Med Imaging; 2011 Jan; 11():1. PubMed ID: 21199574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET.
    Bart J; Willemsen AT; Groen HJ; van der Graaf WT; Wegman TD; Vaalburg W; de Vries EG; Hendrikse NH
    Neuroimage; 2003 Nov; 20(3):1775-82. PubMed ID: 14642487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography.
    Sasongko L; Link JM; Muzi M; Mankoff DA; Yang X; Collier AC; Shoner SC; Unadkat JD
    Clin Pharmacol Ther; 2005 Jun; 77(6):503-14. PubMed ID: 15961982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates.
    Damont A; Goutal S; Auvity S; Valette H; Kuhnast B; Saba W; Tournier N
    Eur J Pharm Sci; 2016 Aug; 91():98-104. PubMed ID: 27283486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional P-glycoprotein activity and inhibition at the human blood-brain barrier as imaged by positron emission tomography.
    Eyal S; Ke B; Muzi M; Link JM; Mankoff DA; Collier AC; Unadkat JD
    Clin Pharmacol Ther; 2010 May; 87(5):579-85. PubMed ID: 20336065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
    Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Stundner G; Karch R; Brauner R; Meier M; Ding X; Müller M; Löscher W; Langer O
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):942-53. PubMed ID: 20016890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil.
    Takano A; Kusuhara H; Suhara T; Ieiri I; Morimoto T; Lee YJ; Maeda J; Ikoma Y; Ito H; Suzuki K; Sugiyama Y
    J Nucl Med; 2006 Sep; 47(9):1427-33. PubMed ID: 16954549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data.
    Hsiao P; Sasongko L; Link JM; Mankoff DA; Muzi M; Collier AC; Unadkat JD
    J Pharmacol Exp Ther; 2006 May; 317(2):704-10. PubMed ID: 16415090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.
    Wanek T; Römermann K; Mairinger S; Stanek J; Sauberer M; Filip T; Traxl A; Kuntner C; Pahnke J; Bauer F; Erker T; Löscher W; Müller M; Langer O
    Mol Pharm; 2015 Sep; 12(9):3214-25. PubMed ID: 26202880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomography imaging of tissue P-glycoprotein activity during pregnancy in the non-human primate.
    Chung FS; Eyal S; Muzi M; Link JM; Mankoff DA; Kaddoumi A; O'Sullivan F; Hsiao P; Unadkat JD
    Br J Pharmacol; 2010 Jan; 159(2):394-404. PubMed ID: 20002098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET.
    Syvänen S; Blomquist G; Sprycha M; Höglund AU; Roman M; Eriksson O; Hammarlund-Udenaes M; Långström B; Bergström M
    Neuroimage; 2006 Sep; 32(3):1134-41. PubMed ID: 16857389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.